Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang, Yu-Chung
Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. [electronic resource] - Annals of hematology Oct 2011 - 1145-51 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1432-0584
10.1007/s00277-011-1268-2 doi
Aged
Antibodies, Monoclonal, Murine-Derived--administration & dosage
Antineoplastic Agents--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
China--epidemiology
Cohort Studies
Disease Susceptibility--chemically induced
Drug Monitoring
Female
Humans
Incidence
Lung Diseases, Interstitial--complications
Lymphocyte Count
Lymphoma, Large B-Cell, Diffuse--blood
Lymphopenia--etiology
Male
Middle Aged
Retrospective Studies
Risk Factors
Rituximab
Survival Analysis
Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. [electronic resource] - Annals of hematology Oct 2011 - 1145-51 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1432-0584
10.1007/s00277-011-1268-2 doi
Aged
Antibodies, Monoclonal, Murine-Derived--administration & dosage
Antineoplastic Agents--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
China--epidemiology
Cohort Studies
Disease Susceptibility--chemically induced
Drug Monitoring
Female
Humans
Incidence
Lung Diseases, Interstitial--complications
Lymphocyte Count
Lymphoma, Large B-Cell, Diffuse--blood
Lymphopenia--etiology
Male
Middle Aged
Retrospective Studies
Risk Factors
Rituximab
Survival Analysis